Here are 14 recent drug shortages and discontinuations, according to FDA drug supply databases:
- Acetaminophen; oxycodone hydrochloride tablet: Multiple strengths of Percocet were discontinued Nov. 3 due to the end of manufacturing.
- Atazanavir sulfate; cobicistat tablet: Evotaz was discontinued Nov. 3. Global manufacturing is expected to cease beginning in April.
- Everolimus tablet: The 2 mg, 3 mg and 5 mg strengths were discontinued Nov. 3.
- Lasmiditan succinate tablet: All 50 mg and 100 mg presentations of Reyvow were discontinued Nov. 3 as a business decision.
- Scopolamine transdermal system: Discontinued Nov. 3.
- Phenobarbital tablet: All strengths — including 16.2 mg, 32.4 mg, 64.8 mg and 97.2 mg — were discontinued Oct. 31.
- Moxifloxacin injection: The 400 mg/250 mL formulation was discontinued Oct. 29.
- Pramlintide acetate injection: SymlinPen 60 and 120 were discontinued Oct. 27.
- Busulfan injection: The 6 mg/mL presentation was discontinued Oct. 24.
- Insulin glargine injection: The Basaglar U-100 Tempo Pen was discontinued Oct. 24.
- Insulin lispro injection: The Humalog U-100 Tempo Pen was discontinued Oct. 24.
- Insulin lispro-aabc injection: The Lyumjev U-100 Tempo Pen and sample were discontinued Oct. 24.
- Lorazepam injection: Currently in shortage due to increased demand.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
